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Purpose: Recently, we reported finding that circulating melatonin levels in age-related macular degeneration patients
were significantly lower than those in age-matched controls. The purpose of this study was to investigate the hypothesis
that melatonin deficiency may play a role in the oxidative damage of the retinal pigment epithelium (RPE) by testing the
protective effect of melatonin and its receptor antagonist on RPE cells exposed to H2O2 damage.
Methods: Cultured human RPE cells were subjected to oxidative stress induced by 0.5 mM H2O2. Cell viability was
measured using the microculture tetrazoline test (MTT) assay. Cells were pretreated with or without melatonin for 24 h.
Luzindole (50 μM), a melatonin membrane-receptor antagonist, was added to the culture 1 h before melatonin to
distinguish direct antioxidant effects from indirect receptor-dependent effects. All tests were performed in triplicate.
Results: H2O2 at 0.5 mM decreased cell viability to 20% of control levels. Melatonin showed dose-dependent protective
effects on RPE cells against H2O2. Cell viability of RPE cells pretreated with 10−10, 10−8, 10−6, and 10−4 M melatonin for
24 h was 130%, 160%, 187%, and 230% of cells treated with H2O2 alone (all p<0.05). Using cells cultured without
H2O2 as the control, cell viability of cells treated with H2O2 after pretreatment with 10−10-10−4 M melatonin was still
significantly lower than that of the controls, suggesting that melatonin significantly decreased but did not completely
abolish the in vitro cytotoxic effects of H2O2. Luzindole completely blocked melatonin’s protective effects at low
concentrations of melatonin (10−10-10−8 M) but not at high concentrations (10−6-10−4 M).
Conclusions: Melatonin has a partial protective effect on RPE cells against H2O2 damage across a wide range of
concentrations (10−10-10−4 M). This protective effect occurs through the activation of melatonin membrane receptors at
low concentrations (10−10-10−8 M) and through both the direct antioxidant and indirect receptor activation effects at high
concentrations (10−6-10−4 M).
Age-related macular degeneration (AMD) is the leading
cause of blindness in aged people in developed countries. The
prevalence of AMD in Americans 40 years of age or older is
1.5%, and it has been estimated that 1.75 million people suffer
from this disease in the United States [1].
The  retinal  pigment  epithelium  is  a  single  layer  of
pigmented cells that have multiple functions essential to the
maintenance of the overlying photoreceptors and hence to
visual function. Oxidative stress has been implicated in the
pathogenesis of AMD, possibly due to the detrimental effects
of  reactive  oxygen  species  (ROS)  on  the  retinal  pigment
epithelial (RPE) cells [2-6]. In support of this hypothesis,
supplementation  with  antioxidants  and  zinc  has  been
demonstrated in several studies to slow the progression of
disease and preserve vision [6,7].
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Recently,  we  found  that  the  amount  of  6-
sulphatoxymelatonin  (aMT6s)  in  nocturnal  urine  (a  well
established  and  reliable  parameter  for  estimating  peak
circulating  melatonin  levels)  in  AMD  patients  was
significantly  lower  than  that  of  age-  and  gender-matched
controls  [8].  Whether  reduced  melatonin  levels  in  AMD
patients play a role in the occurrence of the disease remains
unknown. It is therefore important to study the protective
effects of melatonin on RPE cells against oxidative stress to
determine the relationship between melatonin deficiency and
RPE cell damage. A demonstration of RPE protection by
melatonin  would  support  the  hypothesis  that  melatonin
supplementation  may  be  helpful  for  the  prevention  and
treatment of AMD.
Furthermore, Baba et al. [9] reported that MT1 receptor
transcripts were localized in mouse photoreceptor cells and in
some inner retinal neurons. A diurnal rhythm in the dark-
adapted electroretinography (ERG) responses was observed
in  wild-type  (WT)  mice,  but  not  in  melatonin  membrane
receptor 1 (MT1) receptor-deficient mice [MT1(−/−) mice].
Injection of melatonin during the day influenced ERG in WT
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1640mice  but  not  MT1(−/−)  mice.  MT1(−/−)  mice  showed  a
significant  decrease  of  photoreceptor  nuclei  and  ganglion
cells, compared with WT mice. These results demonstrate the
functional significance of melatonin and MT1 receptors in the
mammalian retina and create the basis for future studies on
the therapeutic use of melatonin in retinal degeneration.
The detrimental effects of H2O2 on various cell types
could be reduced by melatonin in the lymphoma cells [10],
astrocytes [11], breast cancer cells [12], cerebellar granular
neurons [13], pituitary cells [14,15], brain astrocytes [16],
neuroblastoma cells [17], astroglial cells [18], spermatozoa
[19],  hepatoma  cells  [20]  and  motoneurons  [21].  The
mechanism of melatonin mediated cytoprotection has been
documented as a direct antioxidant effect [12], or an indirect
effect via the activation of melatonin receptors and relevant
signal pathways [10,14,21], or through both direct and indirect
effects [16,17], therefore, the melatonin protective effects and
its mechanisms are highly cell type-specific. Very little is
known about melatonin’s ability to protect RPE cells from
H2O2 damage [22]. In this study, we looked at the influence
of  the  dose  and  timing  of  melatonin  administration  on
melatonin’s  ability  to  protect  cultured  human  RPE  cells
against H2O2-induced damage. In addition, the cell cultures
were challenged, with and without the addition of luzindole,
to determine the direct antioxidant versus indirect receptor-
mediated  effects  of  melatonin  across  a  wide  spectrum  of
concentrations.
METHODS
Cell  culture:  The  human  RPE  cell  line,  ARPE-19  (an
immortal cell line from a 19-year-old donor), was obtained
from American Type Culture Collections (Manassas, VA).
Cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM; Gibco, Carlsbad, CA), supplemented with 10% fetal
bovine  serum  (FBS;  Gibco).  Cells  were  incubated  in  a
humidified  5%  CO2  atmosphere  at  37  °C.  After  reaching
confluence, cells were detached by trypsin-EDTA solution
(Gibco), diluted 1:3–1:4, plated for subculture, and passaged
routinely at a dilution of 1:3–1:4 every 5–7 days.
A new separate culture of primary human RPE cells was
isolated from a donor eye (56 years old) and cultured as
previously described [23,24]. Briefly, the anterior segment of
the eye, the vitreous and the retina were excised. The RPE
layer was immersed with trypsin-EDTA solution at 37 °C for
1 h. Culture medium with 10% FBS was added, and the RPE
cells were isolated and collected under direct observation
using a dissecting microscope. Isolated cells were centrifuged,
re-suspended and seeded to a culture flask. Cells were also
cultured in DMEM with 10% FBS. After reaching confluence,
cells  were  subcultured  as  described  above.  Phase-contrast
microscopy revealed pigmentation of RPE cells during the
primary culture and the first and second subcultures. Cells
displayed characteristic epithelial morphology throughout the
culture period. The purity of the cell lines was demonstrated
by immunocytochemical methods. RPE cells display positive
staining of cytokeratin, whereas fibroblasts and melanocytes
do not [25].
Effects of H2O2 on the viability of retinal pigment epithelium
cells: The effects of H2O2 on the viability of RPE cells were
studied with the microculture tetrazoline test (MTT) test as
described previously [24]. Briefly, RPE cells were plated in
96-well plates at a density of 5 × 103 cells per well. After
incubation for 24 h, H2O2 (Sigma, St. Louis, MO) was added
to the wells at various final concentrations (0.05 mM, 0.1 mM,
0.25 mM, 0.5 mM, 0.75 mM, and 1.0 mM) and cultured for
24  h.  Next,  50  µl  of  tetrazolium  bromide,  3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide
( 1   mg/ml;  Sigma),    was     added      to       each      well        and
incubated for 4 h. The medium was withdrawn and 100 µl of
DMSO (Sigma) was added to each well. The optical density
was read at 540 nm using a microplate reader (Multiskan EX;
Thermo, Vantaa, Finland). Cells cultured without H2O2 served
as the controls. The effects of H2O2 on the viability of RPE
cells were studied in the ARPE-19 cell line and the primary-
culture RPE cell line separately. All groups were tested in
triplicate.
Effect  of  melatonin  on  H2O2-induced  damage  in  retinal
pigment epithelium cells: RPE cells were seeded as detailed
above. Twenty-four hours later, melatonin (Sigma) was added
to the culture medium at different concentrations (10−10 M to
10−4 M). After 1 h, 24 h, and 48 h, H2O2 was added to the
medium at a final concentration of 0.5 mM and cultured for
24 h. Then, cell viability was evaluated by the MTT test as
described  above.  Cells  cultured  with  H2O2  but  without
melatonin were used as positive controls. This study was
performed in the ARPE-19 cell line and the primary-culture
RPE cell line separately. All groups were tested in triplicate.
Influence of luzindole on the effects of melatonin on H2O2-
induced damage in retinal pigment epithelium cells: RPE cells
were seeded as previously detailed. After 24 h, luzindole
(Sigma)  was  added  to  the  culture  medium  at  a  final
concentration of 50 μM. One hour later, melatonin was added
to the culture medium at different concentrations (10−10 M to
10−4 M). After 24 h cultivation, H2O2 was added for a final
concentration of 0.5 mM and cultured for 24 h. Then, cell
viability was evaluated by the MTT test described above. This
study  was  performed  in  the  ARPE-19  cell  line  and  the
primary-culture RPE cell line separately. All groups were
tested in triplicate.
Statistical analysis: Statistical significances of differences in
means throughout this study were calculated by an ANOVA
one-way test in comparing data from more than two groups,
and by the Student’s t-test in comparing data between two
groups. A difference at p<0.05 was considered statistically
significant.
RESULTS
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1641Cytotoxic effects of hydrogen peroxide on cultured human
retinal  pigment  epithelium:  H2O2  showed  dose-dependent
cytotoxic effects on cultured human RPE cells (ARPE-19) at
concentrations from 0.25 mM to 1.00 mM (Figure 1 and
Figure 2). Cell viability in cells treated with 0.5 mM H2O2
decreased by 71%, compared to the controls (cells not treated
with H2O2). Therefore, 0.5 mM H2O2 was selected as the
concentration used for subsequent experiments. H2O2 had a
similar cytotoxic effect on the primary-culture human RPE
cells (Figure 2B).
Ability of melatonin to protect retinal pigment epithelium cells
against H2O2 damage: Melatonin at concentrations of 10−10 M
to 10−4 M applied for different time periods did not influence
the cell viability of cultured human RPE cells (ARPE-19 cell
line). Pretreatment of RPE cells with melatonin at low (10−10
M) or high (10−6 M) concentrations for 1 h, 24 h, and 48 h
significantly  protected  cells  against  H2O2  damage  (Figure
3A,B).  Cell  viability  for  cultures  pretreated  with  10−10  M
melatonin for 1 h, 24 h, and 48 h was, respectively, 125%,
133%, and 121% of that of cells treated with H2O2 alone.
Differences  between  cells  cultured  with  and  without
melatonin pretreatment were statistically significant (p<0.05
for all three different pretreatment periods; see Figure 3A).
No significant difference (p>0.05) in cell viability could be
detected between cells pretreated with melatonin at 1 h, 24 h,
and 48 h before challenge (p>0.05). Pretreatment with 10−6 M
melatonin for different periods also significantly protected
cells (p<0.05 in all groups; Figure 3A). No difference in cell
viability  could  be  detected  between  cells  pretreated  with
melatonin  for  different  time  periods  (p>0.05).  Therefore,
pretreatment of melatonin for 24 h was selected for subsequent
experiments. Studies of the primary-culture human RPE cells
from the donors obtained similar results (data not shown).
Pretreatment of melatonin at different concentrations for
24 h showed dose-dependent protective effects on RPE cells
(ARPE-19) against H2O2 damage (Figure 1 and Figure 4A).
Cell viability of RPE cells pretreated with 10−10 M, 10−8 M,
10−6 M, and 10−4 M melatonin was 130%, 160%, 187% and
230%, respectively, of cells treated with H2O2 alone. The
differences in cell viability between cells treated with and
without melatonin were significant (p<0.05) in all groups.
Using cells cultured without H2O2 as the control, the cell
viability of cells treated with H2O2 alone and that of cells
treated with H2O2 after pretreatment with 0 M, 10−10 M, 10−8
M, 10−6 M, and 10−4 M melatonin was 20%, 26%, 31%, 37%,
and 45% of the controls, respectively, which was significantly
lower than the cell viability of cells cultured without H2O2
(one-way  ANOVA,  p>0.05;  see  Figure  5A).  Studies  of
primary-culture  human  RPE  isolated  from  the  donor  eye
showed similar results (Figure 1, Figure 4B, and Figure 5B).
Influence of luzindole on the protective effects of melatonin
on retinal pigment epithelium cells: Cell viability of cultures
treated  with  luzindole  at  50  μM  alone  or  luzindole  with
melatonin at various concentrations (10−10-10−4 M) did not
show any effect in either of the RPE cell lines tested.
Cell viability of ARPE-19 cells (cultured with H2O2) with
luzindole  before  melatonin  was  significantly  decreased,
compared  with  cells  treated  with  melatonin  at  all
concentrations (Figure 1 and Figure 6A). The difference in
cell viability between cells treated with and without luzindole
was  statistically  significant  (p<0.05)  in  cells  treated  with
10−10 M to 10−4 M melatonin.
Figure 1. Melatonin protected the retinal pigment epithelium (RPE) cells against H2O2 damage, especially in high concentrations (10−4 M)
and luzindole decreased the protective effects of melatonin. Phase-contrast microscopic images of the effects of melatonin and its membrane-
receptor antagonist (luzindole) on retinal pigment epithelial cells against H2O2 damage. A-F: The RPE cells are from the ARPE-19 cell line
(an immortal RPE cell line from a 19-year-old donor). G-L: The RPE cells are from the primary culture (PC) from the donor eye. ARPE-19
and PC cells were cultured with or without H2O2, melatonin, and luzindole, as follows: without H2O2, melatonin, and luzindole(A and G);
with H2O2 at 0.5 mM concentrations for 24 h (B and H); with H2O2 and a pretreatment of melatonin at 10−10 M (C and I) or at 10−4 M (D and
J) for 24 h; or with luzindole (50 μM, 1 h), followed by melatonin at 10−10 M (E and K) or at 10−4 M for 24 h (F and L). H2O2 was then added
and the ARPE-19 and PC cells cultured for 24 h.
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1642In cells pretreated with melatonin, the difference between
cell cultures treated with H2O2 alone and cell cultures treated
with  H2O2  plus  melatonin  and  luzindole  was  statistically
nonsignificant (p>0.05) in melatonin at 10−10 M and 10−8 M
(melatonin) and significant (p<0.05) in melatonin at 10−6 M
and 10−4 M, by one-way ANOVA. Studies of primary-culture
human RPE cells isolated from the donor eye showed similar
results (Figure 1 and Figure 6B).
Figure 2. H2O2 dose-dependently decreased cell viability of retinal
pigment epithelial cells as tested by microculture tetrazoline test.
Retinal pigment epithelial (RPE) cells were plated in 96-well plates
and  treated  with  various  concentrations  of  H2O2  for  24  h.  Cell
viability was evaluated by the microculture tetrazoline test (MTT)
test and expressed as percentage of that in cells without H2O2 (mean
±standard deviation [SD] in triplicate tests). A: H2O2 showed dose-
dependent  cytotoxic  effects  on  ARPE-19  cells  (cells  from  an
immortal RPE cell line from a 19-year-old donor) at concentrations
from 0.25 mM to 1.00 mM (p<0.05, compared to cells cultured
without H2O2. B: Studies of primary cultures of human RPE cells
isolated from donor eye showed similar results. *p<0.05, compared
with the controls (cells cultured with H2O2 alone).
DISCUSSION
H2O2 is a relatively weak oxidant, but in the presence of metal
catalysts, it can convert to the reactive hydroxyl radical, which
is cytotoxic. H2O2 is the most stable ROS; it presents in tissues
with a relatively long half-life. H2O2 is soluble in both lipid
and aqueous media, so it can easily diffuse in and out of the
cell to reach targets. For these reasons, H2O2 exposure is one
of  the  most  common  in  vitro  models  used  for  evaluating
oxidative-stress damage on cells [10-22,26].
Previous  studies  have  demonstrated  that  melatonin
protects various cells against H2O2 damage in vitro, and is cell
type-specific [10-21]. Little is known about the protective
effects of melatonin on RPE cells against H2O2 damage. Only
one paper has been published on this subject [22], which tested
Figure 3. The ARPE19 cells (an immortal retinal pigment epithelial
cell line from a 19-year-old donor) were treated with melatonin (M)
at different concentrations. After 1 h, 24 h, and 48 h culture, 0.5 mM
H2O2 (H) was added and cultured for 24 h. Cells cultured with
H2O2 alone were used as the controls. Cell viability was evaluated
by the microculture tetrazoline test and expressed as percentages of
controls (mean±SD in triplicate tests). Error bars represent SD A:
Pretreatment with low concentrations of melatonin at 10−10 M (M-10)
for 1 h, 24 h, and 48 h significantly protected cells against H2O2. B:
Pretreatment with high concentrations of melatonin at 10−6 M (M-6)
obtained similar results. The difference between cells cultured with
and without melatonin at both high and low concentrations was
statistically significant at all three different pretreatment periods.
*p<0.05, compared with the controls.
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1643the effects of melatonin at very high concentrations; and even
the minimum concentration tested (10−7 M) is 100 to 500 fold
the melatonin levels in the serum. The mechanism of the
protective effects (whether a direct antioxidant effect or an
indirect effect through the activation of melatonin receptors)
has not been studied [22].
The  present  study  tested  the  protective  effects  of
melatonin on RPE cells against H2O2 across a wide range of
concentrations. Melatonin showed dose-dependent protective
effects from 10−10 M to 10−4 M. The protective effects present
at both physiologic concentrations (10−10 M to 10−8 M, which
are  1/10  to  10  fold  the  melatonin  serum  levels)  and
pharmacological  concentrations  (10−6  M  to  10−4  M).  Cell
Figure  4.  Melatonin  dose-dependently  protected  retinal  pigment
epithelial  cells  against  H2O2  damage  as  tested  by  microculture
tetrazoline  test.  Retinal  pigment  epithelial  (RPE)  cells  were
pretreated with melatonin (M) at concentrations of 10−10 M (M-10),
10−8 M (M-8), 10−6 M (M-6), and 10−4 M (M-4). After 24 h, 0.5 mM
H2O2 (H) was added and cultured for 24 h. Cells treated with H2O2
alone were used as the controls (H). Cell viability was evaluated by
the microculture tetrazoline test and expressed as percentages of the
controls (mean±standard deviation [SD] in triplicate tests). Error bars
represent SD. Pretreatment with melatonin showed dose-dependent
protective effects on ARPE-19 cells (an immortal RPE cell line from
a 19-year-old donor) against H2O2 damage (A). Studies in primary
culture of human RPE cells isolated from the donor eye showed
similar results (B). *p<0.05, compared with the controls (cells treated
with H2O2 alone).
survival increased by 30%–130% in cells exposed to H2O2
following melatonin pretreatment, compared to those exposed
to  H2O2  alone,  but  the  cell  viability  in  cells  treated  with
melatonin and H2O2 was still lower than that in cells cultured
without  H2O2.  This  suggests  that  melatonin  can  partially
inhibit the cytotoxicity of H2O2 on cultured human RPE cells
and  is  consistent  with  previous  studies  demonstrating  the
protective  effects  of  melatonin  on  other  cells  (neurons,
Figure  5.  Melatonin  dose-dependently  protected  retinal  pigment
epithelial  cells  against  H2O2  damage  as  tested  by  microculture
tetrazoline test, compared with cells not treated with H2O2. Retinal
pigment epithelial (RPE) cells were pretreated with melatonin (M)
at concentrations of 10−10 M (M-10), 10−8 M (M-8), 10−6 M (M-6),
and 10−4 M (M-4). After 24 h, 0.5 mM H2O2 (H) was added and
cultured for 24 h. Cells not treated with H2O2 were used as negative
controls  (0).  Cell  viability  was  evaluated  by  the  microculture
tetrazoline test and expressed as percentages of negative controls
(mean±standard  deviation  [SD]  in  triplicate  tests).  Error  bars
represent SD A: Cell viability of cell treated with melatonin and
H2O2 still significantly lower than that in cells cultured without
H2O2 in the ARPE-19 cells (an immortal RPE cell line from a 19-
year-old donor). B: The same was true in the primary-culture RPE
cells. * p<0.05, compared with the negative controls (cells treated
without H2O2).
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1644astrocytes, pituitary cells, neuroblastoma cells, etc.) exposed
to H2O2 [10-21].
Normal melatonin levels in the serum during the night
have  been  reported  to  vary  from  2  ×  10−10  M  to  10−9  M
[27-29], and the melatonin levels in ocular aqueous humors
have been reported to range from 10−8-10−9 M [30,31]. Urinary
aMT6s levels in AMD patients were 40% lower than in those
of age- and gender-matched controls [8]. The present study
suggests that melatonin at 10−8-10−10 M significantly protects
human RPE cells against H2O2 in a dose-dependent manner.
Figure 6. Luzindole decreased protective effects of melatonin on
retinal pigment epithelial cells against H2O2 damage as tested by
microculture  tetrazoline  test.  Cultured  retinal  pigment  epithelial
(RPE) cells were treated with or without 50 μM luzindole (L). One
hour  later  melatonin  (M)  was  added  to  the  culture  medium  at
concentrations of 10−10 M (M-10), 10−8 M (M-8), 10−6 M (M-6), and
10−4 M (M-4). After 24 h, 0.5 mM H2O2 (H) was added and cultures
were  incubated  for  24  h.  Cell  viability  was  evaluated  by  the
microculture tetrazoline test and expressed as percentages of cells
cultured with H2O2 alone (mean±standard deviation [SD] in triplicate
tests). Error bars represent SD A: Luzindole significantly decreased
melatonin-induced protective effects at 10−10 to 10−4 M in ARPE-19
cells (an immortal RPE cell line from a 19-year-old donor). B: The
same  was  true  in  the  primary-culture  RPE  cells.  *  p<0.05,
comparison between cells treated with and without luzindole.
It corroborates the hypothesis that the deficiency of melatonin
in AMD patients may play a role in the pathogenesis of AMD
and that supplementation of melatonin may be helpful in the
prevention and treatment of AMD.
Melatonin may protect cells against oxidative damage by
at least two mechanisms. At high concentrations, melatonin
may act as a scavenger of free radicals, ROS, and reactive
nitrogen  species.  The  redox  properties  of  melatonin  are
similar  to  those  of  other  tryptophan  metabolites  [32]:
melatonin quenches free radicals (superoxide and hydroxyl
radicals) efficiently but quenches singlet oxygen with only
moderate efficiency [33]. On the other hand, it is able to
activate  membrane-bound  melatonin  receptors,  which  can
stimulate the production of a variety of antioxidative enzymes
through several signaling pathways [21,27,34-40].
To test whether the protective effects of melatonin against
H2O2-induced oxidative stress demonstrated here were due to
direct ROS quenching or due to indirect receptor-mediated
effects,  we  employed  luzindole,  a  melatonin  receptor
antagonist.  Luzindole  is  a  nonselective  antagonist  of
melatonin membrane receptors MT1 and MT2, with a higher
affinity for the MT2 subtype. It has been extensively used to
distinguish  the  direct  antioxidant  effects  from  indirect
receptor-mediated effects [35,41-47].
Very little is known about the effect of luzindole on
melatonin-induced protection of cells against H2O2 damage.
Only one report mentions that luzindole attenuated the effects
of  melatonin-induced  protection  of  motoneurons  against
H2O2  damage,  at  a  single  melatonin  concentration  of
1.5×107 M [21].
Human RPE cells express MT2 but not MT1 melatonin
membrane  receptors  [30,48].  Luzindole  significantly
decreased  the  melatonin-induced  protective  effects  at  all
concentrations  of  melatonin,  indicating  that  the  receptor-
dependent indirect effects are the main protective mechanism
in RPE cells. This is consistent with studies performed on
motoneurons  at  a  single  concentration  [21].  Binding  of
melatonin with its membrane receptors appears to promote
enzymes  that  metabolize  oxidative  stress.  These  enzymes
include  glutathione  peroxidase,  glutathione  reductase,
superoxide dismutases, glucose-6-phosphate dehydrogenase,
and  catalase  [36].  Additionally,  melatonin  receptors  can
couple to multiple signaling pathways, which protects cells
from oxidative stress damage [21].
In  the  present  study,  pretreatment  of  RPE  cells  with
luzindole  decreased  but  did  not  completely  block  the
protective  effects  of  melatonin  at  high  concentrations
(10−6-10−4  M),  suggesting  that  at  pharmacological
concentrations, melatonin may have direct antioxidant effects.
This indicates that luzindole, by blocking the activation of
melatonin membrane receptors, can completely abolish the
protective  effect  of  melatonin  at  low  concentrations.
However,  luzindole  can  reduce,  but  cannot  completely
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against H2O2 damage.
Controversy exists as to whether melatonin can neutralize
H2O2  directly  [36,38].  However,  H2O2  can  convert  to  the
hydroxyl radical, a highly reactive species, which is very toxic
to cells and is the main cause of cell damage from H2O2. The
hydroxyl radical is not enzymatically detoxified within cells
and can only be neutralized by direct free-radical scavengers.
Melatonin interacts with hydroxyl radicals at a rate-constant
that is equivalent to that of other highly efficient hydroxyl
radical scavengers [27,32,34,35,38]. Therefore, this could be
the  mechanism  for  receptor-independent  melatonin
protection.
In  addition  to  the  protective  effects  of  melatonin  on
human RPE cells against oxidative stress, previous studies
have  also  demonstrated  that  melatonin  protects  retinal
homogenates  against  lipid  peroxidation  [49],  and  protects
photoreceptors against various oxidative stressors [50-52].
These studies have also suggested that melatonin may be
beneficial in the management of AMD.
Only one clinical study explored the treatment of AMD
with  melatonin  supplementation:  Yi  et  al.  [53]  reported
encouraging results, but the study was nonrandomized, with
only 6 months of follow-up and an attrition rate at follow-up
of 45%. Still, these results are encouraging for organizing a
randomized clinical trial evaluating the therapeutic value of
melatonin supplementation for AMD management.
Supplementation of melatonin has been widely used in
the treatment of various human disorders. The doses range
from 1 mg to 5 mg per night (low dosage) for treating insomnia
or jet lag [27,54] to 20 mg or more per day (high dosage) for
managing malignant tumors [55]. Patients taking a low dosage
at  night  usually  have  no  significant  side  effects,  whereas
sleepiness, fatigue, seizures, or mild nausea may occur in
patients taking a high dosage [55,56]. If melatonin protects
cells  against  oxidative  stress  only  at  pharmacological
concentrations (10−6-10−4 M), then a high dosage would be
required (e.g., an orally administered dose of 80 mg melatonin
raises  melatonin  serum  levels  from  10−7  M  to  2×10−6  M)
[57]. Our study suggests that melatonin effectively protects
RPE cells at physiologic levels (10−8-10−10 M), which can be
obtained  from  an  orally  administered,  low  dosage  of
melatonin (1–5 mg per night; e.g., an orally administered dose
of 3 mg melatonin has been reported to raise the melatonin
serum  level  to  2×10−8  M)  [28].  This  suggests  that  oral
administration  of  1–3  mg  melatonin  per  night  should  be
sufficient to test the clinical efficacy of melatonin therapy in
AMD patients.
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